Movatterモバイル変換

[0]ホーム

Jump to content

Suvratoxumab

中文

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Suvratoxumab
Monoclonal antibody
Type	?
Source	Human
Target	Staphylococcus aureus alpha toxin
Clinical data
Other names	MEDI4893
ATC code	none
Identifiers
CAS Number	1629620-18-3
ChemSpider	none
UNII	4L1997J4DF
KEGG	D11124
Chemical and physical data
Formula	C₆₅₅₆H₁₀₁₁₄N₁₇₃₀O₂₁₀₀S₄₄
Molar mass	148179.68 g·mol⁻¹

Suvratoxumab (INN;^[1] development codeMEDI4893) is a human monoclonal antibody designed for the prevention ofnosocomial pneumonia caused byStaphylococcus aureus.^[2]

This drug was developed byMedImmune^[3]

References

[edit]

^World Health Organization (2016)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116"(PDF).WHO Drug Information.30 (4).
^Piscaglia M, Scaglione G, Genovese C, Borgonovo F, Brivio F, Rampichini F, et al. (August 2025)."Exploring Human Use of Monoclonal Antibodies Against Critical Bacteria: A Scoping Review of Clinical Trials".Infectious Diseases and Therapy.14 (8):1619–1647.doi:10.1007/s40121-025-01195-2.PMC 12339841.PMID 40715971.
^Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab,American Medical Association.

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Monoclonal antibodies forinfectious disease andtoxins

Fungal

Human	Efungumab^†

Viral

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Clesrovimab Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Pemivibart Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sipavibart Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Toxin

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Retrieved from "https://en.wikipedia.org/w/index.php?title=Suvratoxumab&oldid=1324061894"

Categories:

Hidden categories:

[8]ページ先頭